Literature DB >> 7004338

Comparative activities of cefotiam and cefazolin against urinary tract infections with Proteus mirabilis in mice.

T Iwahi, K Tsuchiya.   

Abstract

The therapeutic effect of cefotiam on experimental urinary tract infections with Proteus mirabilis IFO 3849 in mice was compared with that of cefazolin. The minimal inhibitory concentrations of cefotiam and cefazolin against the test organism were 1.56 and 25 micrograms/ml, respectively. Beginning 3 days after infection, various doses of each cephalosporin were given subcutaneously twice a day for 5 days. Doses of 100 mg of cefotiam per kg or more sterilized the urine within 3 days and effected a marked reduction or complete eradication of bacteria in the bladder walls and kidneys of mice sacrificed the day after treatment was terminated. A dose of cefazolin greater than 800 mg/kg was required for equivalent therapeutic results. Clearance of bacteria from urinary tract organs was as rapid or more rapid with 50-mg/kg doses of cefotiam as with 200-mg/kg doses of cefazolin. Much more rapid clearance was attained with 200-mg/kg doses of cefotiam. The concentrations of cefotiam attained in plasma, kidney, and urine were lower than the cefazolin levels achieved at an equivalent dose. The superiority of cefotiam over cefazolin in treatment of experimental urinary tract infections appears to be due to its greater activity against the test organism.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7004338      PMCID: PMC283980          DOI: 10.1128/AAC.18.2.257

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  "Continuous" vs. "discontinuous" therapy with penicillin; the effect of the interval between injections on therapeutic efficacy.

Authors:  H EAGLE; R FLEISCHMAN; M LEVY
Journal:  N Engl J Med       Date:  1953-03-19       Impact factor: 91.245

2.  Effect of schedule of administration on the therapeutic efficacy of penicillin; importance of the aggregate time penicillin remains at effectively bactericidal levels.

Authors:  H EAGLE; R FLEISCHMAN; A D MUSSELMAN
Journal:  Am J Med       Date:  1950-09       Impact factor: 4.965

3.  The effective concentrations of penicillin in vitro and in vivo for streptococci, pneumococci, and Treponema pallidum.

Authors:  H EAGLE; R FLEISCHMAN; A D MUSSELMAN
Journal:  J Bacteriol       Date:  1950-05       Impact factor: 3.490

4.  Cefazolin and cephradine: relationship between antibacterial activity in vitro and in mice experimentally infected with Escherichia coli.

Authors:  M W Kunst; H Mattie
Journal:  J Infect Dis       Date:  1978-04       Impact factor: 5.226

5.  Absorption, distribution and excretion of SCE-963, a new broad-spectrum cephalosporin, in mice, rats, rabbits and dogs.

Authors:  K Tsuchiya; M Kondo; Y Kita; Y Noji; M Takeuchi; T Fugono
Journal:  J Antibiot (Tokyo)       Date:  1978-12       Impact factor: 2.649

6.  Experimental urinary tract infection with Pseudomonas aeruginosa in mice.

Authors:  T Nishi; K Tsuchiya
Journal:  Infect Immun       Date:  1978-11       Impact factor: 3.441

7.  SCE-963, a new broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kida; M Kondo; H Ono; M Takeuchi; T Nishi
Journal:  Antimicrob Agents Chemother       Date:  1978-10       Impact factor: 5.191

  7 in total
  2 in total

1.  Pharmacokinetics of cefotiam in normal humans.

Authors:  F D Daschner; K A Hemmer; P Offermann; J Slanicka
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

2.  Cefmenoxime (SCE-1365), a novel broad-spectrum cephalosporin: in vitro and in vivo antibacterial activities.

Authors:  K Tsuchiya; M Kondo; M Kida; M Nakao; T Iwahi; T Nishi; Y Noji; M Takeuchi; Y Nozaki
Journal:  Antimicrob Agents Chemother       Date:  1981-01       Impact factor: 5.191

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.